Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to assess the effect of Antrodia cinnamomea mycelia on immune modulation in subhealth people.
This study aims to assess the effect of Antrodia cinnamomea mycelia on immune modulation in subhealth people: a randomized, double-blind, placebo-controlled, and parallel clinical investigation.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo | Placebo Comparator | Placeo group |
|
| Treatment | Experimental | Experimental group |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Antrodia cinnamomea mycelia | Dietary Supplement | Antrodia cinnamomea mycelia capsule, two capsules/day (600 mg/day) for 3 months |
|
| Measure | Description | Time Frame |
|---|---|---|
| Immune analysis | Changes in T cell markers of 29 participants will be analyzed between baseline and week 4. | Baseline up to 4 weeks |
| Immune analysis | Changes in B cell markers of 29 participants will be analyzed between baseline and week 4. | Baseline up to 4 weeks |
| Antibody analysis | Changes in IgA levels of 29 participants will be analyzed between baseline and week 4. | Baseline up to 4 weeks |
| Antibody analysis | Changes in IgD levels of 29 participants will be analyzed between baseline and week 4. | Baseline up to 4 weeks |
| Antibody analysis | Changes in IgG levels of 29 participants will be analyzed between baseline and week 4. | Baseline up to 4 weeks |
| Antibody analysis | Changes in IgE levels of 29 participants will be analyzed between baseline and week 4. | Baseline up to 4 weeks |
| Antibody analysis | Changes in IgM levels of 29 participants will be analyzed between baseline and week 4. | Baseline up to 4 weeks |
| Cytokine analysis |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ming-Shun Wu, MD | WanFang Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| WanFang Hospital | Taipei | 116 | Taiwan |
Not provided
| ID | Term |
|---|---|
| D015673 | Fatigue Syndrome, Chronic |
| D003139 | Common Cold |
| ID | Term |
|---|---|
| D009135 | Muscular Diseases |
| D009140 | Musculoskeletal Diseases |
| D004679 | Encephalomyelitis |
| D000090862 | Neuroinflammatory Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Dietary Supplement | Placebo capsule, two capsules/day (600 mg/day) for 3 months |
|
Changes in IL-1beta levels of 29 participants will be analyzed between baseline and week 4.
| Baseline up to 4 weeks |
| Cytokine analysis | Changes in IL-4 levels of 29 participants will be analyzed between baseline and week 4. | Baseline up to 4 weeks |
| Cytokine analysis | Changes in IL-6 levels of 29 participants will be analyzed between baseline and week 4. | Baseline up to 4 weeks |
| Cytokine analysis | Changes inFN-gamma levels of 29 participants will be analyzed between baseline and week 4. | Baseline up to 4 weeks |
| Cytokine analysis | Changes in TNF-alpha levels of 29 participants will be analyzed between baseline and week 4. | Baseline up to 4 weeks |
| D009422 | Nervous System Diseases |
| D009468 | Neuromuscular Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D010850 | Picornaviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D012140 | Respiratory Tract Diseases |